What's the Score? Do Pleural Effusion Clinical Scoring Systems Help in Management of Disease?

Abstract Pleural effusion is a common condition, affecting over 3,000 people per million population every year. More than 50 causes of pleural effusions are known, including pleural infection and malignant pleural disease. These conditions place a large burden on healthcare systems with one-fourth of patients with pleural infection having a length of hospital stay of more than 1 month. Malignant pleural effusion represents advanced malignant disease with a correspondingly high mortality. Prognostic models using clinical information in combination with blood or pleural fluid biomarkers predicting survival and other outcome measures are therefore a priority in improving clinical care, and potentially outcomes. Identifying patients with poor prognosis may help avoid discomfort and unnecessary interventions at the end of their lives, while, on the other hand, individuals with scores predicting a particularly good prognosis might be selected for more aggressive early treatment. Such scores must be based on data representing routine practice in a general hospital and variables chosen based on their clinical availability at clinical decision points (i.e., before treatment is instituted), making the findings widely applicable.

[1]  H. Jones,et al.  Interventions for the management of malignant pleural effusions: a network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[2]  N. Rahman,et al.  Thoracic Ultrasound as an Early Predictor of Pleurodesis Success in Malignant Pleural Effusion , 2018, Chest.

[3]  T. Henry,et al.  Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[4]  I. Pavord,et al.  Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. , 2018, The Lancet. Oncology.

[5]  J. M. Porcel,et al.  Development and validation of a scoring system for the identification of pleural exudates of cardiac origin. , 2017, European journal of internal medicine.

[6]  H. Davies,et al.  Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion , 2017, American journal of respiratory and critical care medicine.

[7]  J. Latour‐Pérez,et al.  Diaphragm and Lung Ultrasound to Predict Weaning Outcome: Systematic Review and Meta‐Analysis , 2017, Chest.

[8]  N. Rahman,et al.  Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial , 2017, BMJ Open Respiratory Research.

[9]  N. Rahman,et al.  Assessment of patient-reported outcome measures in pleural interventions , 2017, BMJ Open Respiratory Research.

[10]  A. Tremblay,et al.  US Hospitalizations for Malignant Pleural Effusions: Data From the 2012 National Inpatient Sample , 2017, Chest.

[11]  N. Rahman,et al.  Ultrasound in the management of pleural disease , 2017, Expert review of respiratory medicine.

[12]  J. M. Porcel,et al.  Malignant pleural effusion: from bench to bedside , 2016, European Respiratory Review.

[13]  Anoop Chauhan,et al.  Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. , 2015, JAMA.

[14]  N. Maskell,et al.  The modern diagnosis and management of pleural effusions , 2015, BMJ : British Medical Journal.

[15]  D. Feller-Kopman,et al.  Pleural infection: past, present, and future directions. , 2015, The Lancet. Respiratory medicine.

[16]  D. Fielding,et al.  Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage. , 2014, Chest.

[17]  Brennan C Kahan,et al.  Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score , 2014, Thorax.

[18]  F. Gleeson,et al.  A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection. , 2014, Chest.

[19]  M. Cunniffe,et al.  Video-assisted thoracoscopic surgery in the management of loculated empyema , 2000, Surgical Endoscopy.

[20]  H. Davies,et al.  Management of malignant pleural effusions: questions that need answers , 2013, Current opinion in pulmonary medicine.

[21]  R. Davies,et al.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. , 2012, JAMA.

[22]  J. M. Porcel,et al.  Solving the Light's criteria misclassification rate of cardiac and hepatic transudates , 2012, Respirology.

[23]  R. Ramakrishnan,et al.  Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  T. Pruett Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection , 2012 .

[25]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[26]  J. Porcel,et al.  Pleural Effusions from Congestive Heart Failure , 2010, Seminars in respiratory and critical care medicine.

[27]  N. Pavlakis,et al.  High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy , 2010, Clinical Cancer Research.

[28]  P. Goldstraw,et al.  Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Edmund Neville,et al.  Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[30]  A. Balci,et al.  Predictors of mortality within three months in the patients with malignant pleural effusion. , 2010, European journal of internal medicine.

[31]  S. Bielsa,et al.  Biomarkers of heart failure in pleural fluid. , 2009, Chest.

[32]  J. M. Porcel,et al.  Prognostic significance of pleural fluid data in patients with malignant effusion. , 2008, European journal of internal medicine.

[33]  J. Yee,et al.  Empyema: an increasing concern in Canada. , 2008, Canadian respiratory journal.

[34]  Jeng-shing Wang,et al.  Improved lung function after thoracocentesis in patients with paradoxical movement of a hemidiaphragm secondary to a large pleural effusion , 2007, Respirology.

[35]  J. M. Porcel,et al.  Comparing serum and pleural fluid pro‐brain natriuretic peptide (NT‐proBNP) levels with pleural‐to‐serum albumin gradient for the identification of cardiac effusions misclassified by Light's criteria , 2007, Respirology.

[36]  D. Flum,et al.  Management of pleural space infections: a population-based analysis. , 2007, The Journal of thoracic and cardiovascular surgery.

[37]  T. Treasure,et al.  The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[38]  R. Davies,et al.  U.K. Controlled trial of intrapleural streptokinase for pleural infection. , 2005, The New England journal of medicine.

[39]  R. Light,et al.  Efficacy of ultrasound in the diagnosis of pleurodesis in rabbits. , 2004, Chest.

[40]  P. Goldstraw,et al.  Management of malignant pleural effusions. , 2001, The European respiratory journal.

[41]  J. M. Porcel,et al.  Measurement of pro-brain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. , 2004, The American journal of medicine.

[42]  R. Light,et al.  Prognostic features of residual pleural thickening in parapneumonic pleural effusions , 2003, European Respiratory Journal.

[43]  Concepción Martín,et al.  Is it meaningful to use biochemical parameters to discriminate between transudative and exudative pleural effusions? , 2002, Chest.

[44]  A. Rengarajan,et al.  Delayed referral reduces the success of video-assisted thoracoscopic debridement for post-pneumonic empyema. , 2001, Respiratory Medicine.

[45]  H. Colt,et al.  Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. , 2000, Chest.

[46]  W. Vigneswaran,et al.  Surgical Strategy of Complex Empyema Thoracis , 2000, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[47]  E. Kalso,et al.  Chronic pain after thoracic surgery: a follow‐up study , 1999, Acta anaesthesiologica Scandinavica.

[48]  F. Gleeson,et al.  Predictors of outcome and long-term survival in patients with pleural infection. , 1999, American journal of respiratory and critical care medicine.

[49]  P. Pairolero,et al.  Video-assisted thoracic surgical procedures: the Mayo experience. , 1996, Mayo Clinic proceedings.

[50]  Jeng-shing Wang,et al.  Changes in pulmonary mechanics and gas exchange after thoracentesis on patients with inversion of a hemidiaphragm secondary to large pleural effusion. , 1995, Chest.

[51]  M. Tattersall,et al.  Management of malignant pleural effusions. , 1990, Thorax.

[52]  R. Light,et al.  Parapneumonic effusions. , 1980, The American journal of medicine.

[53]  W. C. Ball,et al.  Pleural effusions: the diagnostic separation of transudates and exudates. , 1972, Annals of internal medicine.